Clinical Trial

Platelet Rich Plasma for Musculoskeletal Conditions

Study acronym: PRP for MSK
Recruiting
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-13; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2026-03-19
Trial Details
NCT Number NCT07231471
Lead Sponsor University of Utah
Conditions Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Shoulder, Osteoarthritis Ankle, Elbow Osteoarthritis, Epicondylitis of the Elbow, Plantar Fasciitis of Both Feet +1 more
Enrollment 10,000 participants
Start Date 2025-12-29
Primary Completion 2035-01-01 (estimated)
Study Completion 2035-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06